Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Curr Med Chem. 2019;26(41):7452-7475. doi: 10.2174/0929867325666180914104237.
The development of safe and effective chemotherapeutic agents is one of the uppermost priorities and challenges of medicinal chemistry and new transition metal complexes are being continuously designed and tested as anticancer agents. Scorpionate ligands have played a great role in coordination chemistry, since their discovery by Trofimenko in the late 1960s, with significant contributions in the fields of catalysis and bioinorganic chemistry. Scorpionate metal complexes have also shown interesting anticancer properties, and herein, the most recent (last decade) and relevant scorpionate complexes reported for application in medicinal chemistry as chemotherapeutic agents are reviewed. The current progress on the anticancer properties of transition metal complexes bearing homo- or hetero- scorpionate ligands, derived from bis- or tris-(pyrazol-1-yl)-borate or -methane moieties is highlighted.
开发安全有效的化疗药物是药物化学的首要任务和挑战之一，新型过渡金属配合物作为抗癌药物不断被设计和测试。自从 20 世纪 60 年代晚期 Trofimenko 发现以来，Schiff 碱配体在配位化学中发挥了重要作用，在催化和生物无机化学领域做出了重大贡献。Schiff 碱金属配合物也表现出了有趣的抗癌特性，本文综述了近十年来报道的用于药物化学作为化疗药物的最新型（最近十年）Schiff 碱配合物。重点介绍了源自双（或三）（吡唑-1-基）硼酸酯或甲烷部分的同型或异型Schiff 碱配体的过渡金属配合物的抗癌特性的最新进展。
